Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top 10 Drugs Of 2020: #4 Eliquis

Leapfrogging The Competition

You may also be interested in...



Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

CEO Caforio used the J.P. Morgan stage to try to assuage Celgene investors who recently lost out on a $9 CVR under the buyout, playing up the long-term promise of the combined company. 

Medicare Part D’s ‘Catastrophic Cliff’ Slows Eliquis, Trulicity Sales In Third Quarter

Pfizer, BMS and Lilly see sales impacted by Part D changes that leave some beneficiaries in the coverage gap longer this year, extending manufacturer discount obligations.

Bristol Highlights Growth Is Not Coming From Opdivo Alone

Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel